CD34 and age-related macular degeneration: Cotrim and colleagues reported that the intravitreal use of a bone marrow mononuclear fraction containing CD34+ cells in a small cohort of patients with atrophic AMD was safe and resulted in a small improvement in best corrected visual acuity [39].